Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$291.17
-0.6%
$288.02
$253.30
$335.88
$156.75B0.492.72 million shs485,848 shs
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$43.73
-0.2%
$45.84
$42.96
$63.33
$88.92B0.3313.55 million shs4.14 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$87.73
+0.6%
$84.37
$73.31
$106.49
$219.06B0.3714.69 million shs3.00 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-1.04%-0.99%+2.12%-4.47%-6.99%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-1.24%+1.02%-2.29%-9.55%-17.43%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.41%+4.21%+9.21%+2.86%-17.99%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$291.17
-0.6%
$288.02
$253.30
$335.88
$156.75B0.492.72 million shs485,848 shs
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$43.73
-0.2%
$45.84
$42.96
$63.33
$88.92B0.3313.55 million shs4.14 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$87.73
+0.6%
$84.37
$73.31
$106.49
$219.06B0.3714.69 million shs3.00 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-1.04%-0.99%+2.12%-4.47%-6.99%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-1.24%+1.02%-2.29%-9.55%-17.43%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.41%+4.21%+9.21%+2.86%-17.99%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.28
Hold$300.943.36% Upside
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.35
Hold$57.2330.88% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.30
Hold$104.3318.92% Upside

Current Analyst Ratings Breakdown

Latest MRK, AMGN, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/24/2025
Amgen Inc. stock logo
AMGN
Amgen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy (B-)
10/14/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/13/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
10/13/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$84.00 ➝ $95.00
10/8/2025
Amgen Inc. stock logo
AMGN
Amgen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+)Buy (B-)
10/8/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/2/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Dbs Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeModerate Buy
9/27/2025
Amgen Inc. stock logo
AMGN
Amgen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
9/27/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
9/26/2025
Amgen Inc. stock logo
AMGN
Amgen
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderperform$261.00 ➝ $272.00
(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.69$29.86 per share9.75$10.93 per share26.64
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$47.70B1.87$5.80 per share7.54$8.08 per share5.41
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.42$9.47 per share9.26$18.33 per share4.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$12.2323.8113.612.6218.96%174.71%13.12%11/4/2025 (Estimated)
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-$8.95B$2.4817.617.182.3210.58%80.04%14.69%10/30/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.4913.518.860.9625.79%41.05%16.55%10/30/2025 (Estimated)

Latest MRK, AMGN, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2025Q3 2025
Amgen Inc. stock logo
AMGN
Amgen
$5.01N/AN/AN/A$8.98 billionN/A
10/30/2025Q3 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.65N/AN/AN/A$11.75 billionN/A
10/30/2025Q3 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.37N/AN/AN/A$17.00 billionN/A
8/5/2025Q2 2025
Amgen Inc. stock logo
AMGN
Amgen
$5.28$6.02+$0.74$2.65$8.86 billion$9.18 billion
7/31/2025Q2 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.07$1.46+$0.39$0.64$11.32 billion$12.27 billion
7/29/2025Q2 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.523.27%N/A77.84%14 Years
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.485.67%N/A100.00%17 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.69%N/A49.92%14 Years

Latest MRK, AMGN, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/17/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.625.46%10/3/202510/3/202511/3/2025
8/1/2025
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.383.21%8/22/20258/22/20259/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
7.24
1.31
0.98
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.54
1.21
1.11
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.69
1.42
1.17

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.76%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.09%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000538.36 million534.27 millionOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
34,1002.04 billion2.03 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.50 billion2.49 billionOptionable

Recent News About These Companies

Merck & Co., Inc. $MRK Shares Bought by 180 Wealth Advisors LLC
5 Best Dividend Stocks in the S&P 500

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amgen stock logo

Amgen NASDAQ:AMGN

$291.17 -1.72 (-0.59%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$43.73 -0.10 (-0.23%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$87.73 +0.55 (+0.63%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.